Lifeboat Foundation: Safeguarding Humanity
Toggle light / dark theme

Blog

Category: biotech/medical – Page 196

Signature in blood to better predict type 2 diabetes risk

The metabolites associated with type 2 diabetes were also found to be genetically linked to clinical traits and tissue types that are relevant to the disease. Furthermore, the team developed a unique signature of 44 metabolites that improved prediction of future risk of type 2 diabetes. ScienceMission sciencenewshighlights.

Diabetes, a metabolic disease, is on the rise worldwide, and over 90 percent of cases are type 2 diabetes, where the body does not effectively respond to insulin. Researchers identified metabolites (small molecules found in blood generated through metabolism associated with risk of developing type 2 diabetes in the future and revealed genetic and lifestyle factors that may influence these metabolites. They also developed a metabolomic signature that predicts future risk of type 2 diabetes beyond traditional risk factors. Their results are published in Nature Medicine.

In this study, researchers tracked 23,634 individuals with diverse ethnic backgrounds across 10 prospective cohorts with up to 26 years of follow-up. These individuals were initially free of type 2 diabetes. The team analyzed 469 metabolites in blood samples, as well as genetic, diet, and lifestyle data, to see how they relate to risk of developing type 2 diabetes. Of the metabolites examined, 235 were found to be associated with a higher or lower risk of developing type 2 diabetes, 67 of which were new discoveries.

“Interestingly, we found that diet and lifestyle factors may have a stronger influence on metabolites linked to type 2 diabetes than on metabolites not associated with the disease,” said first and co-corresponding author. “This is especially true for obesity, physical activity, and intake of certain foods and beverages such as red meat, vegetables, sugary drinks, and coffee or tea. Increasing evidence suggests that these dietary and lifestyle factors are associated with greater or lower risk of type 2 diabetes. Our study revealed that specific metabolites may act as potential mediators, linking these factors with type 2 diabetes risk.”

Substituting stereotactic body radiation therapy boost for brachytherapy in Mayo protocol for peri-hilar cholangiocarcinoma

Blood vessels are less like straight pipes and more like a crowded city road map, with turns, forks, and sudden choke points that can change how traffic moves. For a long time, many lab built vessel models skipped that complexity and relied on simple, straight channels, even though real vessels rarely behave that neatly.

Researchers in the Department of Biomedical Engineering at Texas A&M University are trying to close that gap with a customizable vessel-chip method. The goal is to recreate the kinds of shapes that matter in disease, so experiments on blood flow and potential treatments reflect what happens in the body more closely and can better support drug discovery.

Vessel-chips are engineered microfluidic devices that mimic human vasculature on a microscopic scale. Instead of studying blood flow in animals or oversimplified lab setups, scientists can use these chips to examine how fluid forces move through vessel-like structures in a controlled environment. Because the design can be tailored, the platform can also support patient-focused studies, which is especially useful when small differences in anatomy may affect how disease develops or how a therapy performs.

How the Incas Performed Skull Surgery More Successfully Than U.S. Civil War Doctors

Granted access to a time machine, few of us would presumably opt first for the experience of skull surgery by the Incas. Yet our chances of survival would be better than if we underwent the same procedure 400 years later, at least if it took place on a Civil War battlefield.

Researchers identify new blood markers that may detect early pancreatic cancer

NIH-funded, four-marker panel could one day help catch one of deadliest cancers at more treatable stages.

National Institutes of Health (NIH)-supported investigators have developed a blood test to find pancreatic ductal adenocarcinoma, one of the deadliest forms of cancer. The new test could improve survival rates from pancreatic cancer, which tends to be diagnosed at late stages when therapy is less likely to be effective. The findings were published in Clinical Cancer Research.

Overall, only about 1 in 10 pancreatic cancer patients survive more than five years from diagnosis. However, experts expect that when the cancer is found and treated at an earlier stage, survival would improve. While finding the cancer early is key, there are no current screening methods to do so.

How a broken DNA repair tool accelerates aging

Although DNA is tightly packed and protected within the cell nucleus, it is constantly threatened by damage from normal metabolic processes or external stressors such as radiation or chemical substances. To counteract this, cells rely on an elaborate network of repair mechanisms. When these systems fail, DNA damage can accumulate, impair cellular function, and contribute to cancer, aging, and degenerative diseases.

One particularly severe form of DNA damage are the so-called DNA–protein crosslinks (DPCs), in which proteins become attached to DNA. DPCs can arise from alcohol consumption, exposure to substances such as formaldehyde or other aldehydes, or from errors made by enzymes involved in DNA replication and repair. Because DPCs can cause serious errors during cell division by stalling DNA replication, DNA–protein crosslinks pose a serious threat to genome integrity.

The enzyme SPRTN removes DPCs by cleaving the DNA-protein crosslinks. SPRTN malfunctions, for example as a result of mutations, may predispose individuals to developing bone deformities and liver cancer in their teenage years. This rare genetic disorder is known as Ruijs-Aalfs syndrome. Its underlying mechanism remains poorly understood, and there are no specific therapies.

Scientists teach microorganisms to build molecules with light

Researchers are continually looking for new ways to hack the cellular machinery of microbes like yeast and bacteria to make products that are useful for humans and society. In a new proof-of-concept study, a team from the Carl R. Woese Institute for Genomic Biology showed they can expand the biosynthetic capabilities of these microbes by using light to help access new types of chemical transformations.

The paper, published in Nature Catalysis, demonstrates how the bacteria Escherichia coli can be engineered to produce these new molecules in vivo, using light-driven enzymatic reactions. This framework sets the foundation for future development in the emerging field of photobiocatalysis.

“Photobiocatalysis is basically light-activated catalysis by enzymes. Without light, the target enzyme cannot catalyze a reaction. When light is added, the target enzyme will be activated,” said Huimin Zhao (BSD leader/CAMBERS/CGD/MMG), Steven L. Miller Chair of Chemical and Biomolecular Engineering. “We have published many papers showing that it is possible to combine photocatalysis with enzyme catalysis to create a new class of photoenzymes. These artificial photoenzymes can catalyze selective reactions that cannot be achieved by natural enzymes and are also very difficult, or sometimes even not possible, with chemical catalysis.”

Immunoglobulin G’s overlooked hinge turns out to be a structural control hub

The lower hinge of immunoglobulin G (IgG), an overlooked part of the antibody, acts as a structural and functional control hub, according to a study by researchers at Science Tokyo. Deleting a single amino acid in this region transforms a full-length antibody into a stable half-IgG1 molecule with altered immune activity.

The findings provide a blueprint for engineering next-generation antibody therapies with precisely tailored immune effects for treating diseases such as cancer and autoimmune diseases.

Antibodies are Y-shaped proteins that help the immune system recognize and eliminate foreign threats such as bacteria and viruses. The dominant antibody in the bloodstream is immunoglobulin G (IgG), which accounts for about 75% of circulating antibodies. Its structure is divided into two main functional units connected by a flexible hinge that must work together seamlessly.

/* */